Deutsche Bank has initiated coverage on Apogee Therapeutics Inc (APGE) with a Buy rating, marking the firm's first assessment of the biotechnology company. This rating reflects Deutsche Bank's analysis of Apogee's business, industry dynamics, and growth prospects.
Headquartered in Waltham, Massachusetts, Apogee Therapeutics operates in the biotechnology sector and currently employs 196 full-time staff. The company went public on July 14, 2023, and is focused on developing novel biologics aimed at treating various inflammatory and immunological conditions, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease. Its most advanced program, APG777, is being developed for the treatment of atopic dermatitis, while the company has other promising candidates in its pipeline, such as APG990, APG333, and APG808.
As of December 1, 2025, analyst consensus on Apogee Therapeutics stands at 9 Strong Buy, 8 Buy, and 1 Hold, indicating a generally favorable outlook among analysts. The company's market capitalization is approximately $3.6 billion, with a trailing twelve-month earnings per share (EPS) of -4.12. Upcoming earnings are anticipated on May 11, 2026, with an estimated EPS of -1.11.
Analyst ratings and price targets are informed by research and financial models, providing valuable perspectives, although they are based on assumptions that may not always materialize. Investors are encouraged to consider a range of factors, including company fundamentals and industry trends, before making decisions.
This update provides insight into Apogee Therapeutics' potential as a growing player in the biotechnology space, supported by Deutsche Bank's endorsement.